H1 Blog
NOVEMBER 15, 2023
The compensation provided to KOLs should also be fair-market value for their time and effort, and not an inducement for them to prescribe or recommend specific products. Furthermore, the interactions between life sciences companies and KOLs should be transparent and properly documented.
The Pharma Data
SEPTEMBER 11, 2020
In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US.
PerkinElmer
FEBRUARY 18, 2021
Dr. Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings.
Expert insights. Personalized for you.
59 
Let's personalize your content